ATE487492T1 - Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit - Google Patents
Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeitInfo
- Publication number
- ATE487492T1 ATE487492T1 AT04714961T AT04714961T ATE487492T1 AT E487492 T1 ATE487492 T1 AT E487492T1 AT 04714961 T AT04714961 T AT 04714961T AT 04714961 T AT04714961 T AT 04714961T AT E487492 T1 ATE487492 T1 AT E487492T1
- Authority
- AT
- Austria
- Prior art keywords
- drug dependence
- pharmaceutical composition
- treating drug
- treating
- dependence
- Prior art date
Links
- 206010013663 drug dependence Diseases 0.000 title abstract 3
- 208000011117 substance-related disease Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract 1
- 229960004373 acetylcholine Drugs 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000012907 medicinal substance Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44986803P | 2003-02-27 | 2003-02-27 | |
PCT/JP2004/002301 WO2004075916A1 (en) | 2003-02-27 | 2004-02-26 | Pharmaceutical composition for treatment of drug dependence |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE487492T1 true ATE487492T1 (de) | 2010-11-15 |
Family
ID=32927586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04714961T ATE487492T1 (de) | 2003-02-27 | 2004-02-26 | Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060058336A1 (de) |
EP (1) | EP1603595B1 (de) |
JP (1) | JP2006519225A (de) |
AT (1) | ATE487492T1 (de) |
AU (1) | AU2004216360B2 (de) |
CA (1) | CA2516618A1 (de) |
DE (1) | DE602004029993D1 (de) |
WO (1) | WO2004075916A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
WO2003032914A2 (en) * | 2001-10-17 | 2003-04-24 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
WO2006013546A2 (en) * | 2004-07-28 | 2006-02-09 | Ranbaxy Laboratories Limited | Process for the preparation of pure galantamine |
RU2491067C2 (ru) | 2007-08-06 | 2013-08-27 | Байотай Терапис, Инк | Способы лечения зависимости |
CN102573848A (zh) * | 2009-04-24 | 2012-07-11 | 济州大学校产学协力团 | 含有去甲加兰他敏化合物作为活性成分的用于预防和治疗脱发症的组合物 |
KR101037237B1 (ko) | 2009-04-24 | 2011-05-25 | 충남대학교산학협력단 | 노르갈란타민 화합물을 유효성분으로 함유하는 탈모 질환의 예방 및 치료용 조성물 |
KR101037235B1 (ko) | 2009-04-24 | 2011-05-25 | 충남대학교산학협력단 | 노르갈란타민 화합물을 유효성분으로 함유하는 탈모 방지 및 발모 개선용 조성물 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
US5262165A (en) * | 1992-02-04 | 1993-11-16 | Schering Corporation | Transdermal nitroglycerin patch with penetration enhancers |
US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
DE69229781T2 (de) * | 1991-05-14 | 2000-01-05 | Ernir Snorrason | Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren |
US6010715A (en) * | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
US5278176A (en) * | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
DE4301782C1 (de) * | 1993-01-23 | 1994-08-25 | Lohmann Therapie Syst Lts | Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit |
AU1884595A (en) * | 1994-04-29 | 1995-11-29 | Pfizer Inc. | Novel acyclic and cyclic amides as neurotransmitter release enhancers |
DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
PL181582B1 (pl) * | 1995-06-07 | 2001-08-31 | Ortho Mcneil Pharm Inc | Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL |
US5824684A (en) * | 1997-02-21 | 1998-10-20 | Synapse Pharmaceuticals International, Inc. | Method for treating drug and alcohol addiction |
GB9716879D0 (en) * | 1997-08-08 | 1997-10-15 | Shire Int Licensing Bv | Treatment of attention deficit disorders |
DK1024807T3 (da) * | 1997-08-08 | 2003-08-04 | Medosan Ricerca Srl | Anvendelse af forbindelsen 2-methoxyphenyl-1-methyl-5p-methylbenzoyl-pyrrol-2-acetamidoacetat for fremstilling af et anti-inflammatorisk medikament med forhindring af gastrisk hypersecernering og forstyrrelse af nyrefunktionen |
US5948433A (en) * | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
DE19738855C2 (de) * | 1997-09-05 | 2001-01-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht |
JP3992806B2 (ja) * | 1997-12-12 | 2007-10-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ドネペジル中間体の製造法 |
IL125809A (en) * | 1998-08-17 | 2005-08-31 | Finetech Lab Ltd | Process and intermediates for production of donepezil and related compounds |
PT1311272E (pt) * | 2000-03-03 | 2007-02-28 | Eisai R&D Man Co Ltd | Novos métodos utilizando inibidores de colinesterase |
US20030153598A1 (en) * | 2000-07-25 | 2003-08-14 | Raymond Pratt | Methods for treating Parkinson's disease with cholinesterase inhibitors |
US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
AU2002229101A1 (en) * | 2000-12-20 | 2002-07-01 | Michigan Biotechnology Institute | Soy milk juice beverage |
DE10119862A1 (de) * | 2001-04-24 | 2002-11-07 | Hf Arzneimittelforsch Gmbh | Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen |
WO2003024450A1 (en) * | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
WO2003032914A2 (en) * | 2001-10-17 | 2003-04-24 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
JP2004189706A (ja) * | 2002-12-13 | 2004-07-08 | Eisai Co Ltd | 高度アルツハイマー型痴呆治療剤 |
US20050018839A1 (en) * | 2003-07-23 | 2005-01-27 | Weiser William Bruce | Electronic device cradle organizer |
-
2004
- 2004-02-26 CA CA002516618A patent/CA2516618A1/en not_active Abandoned
- 2004-02-26 WO PCT/JP2004/002301 patent/WO2004075916A1/en active Application Filing
- 2004-02-26 DE DE602004029993T patent/DE602004029993D1/de not_active Expired - Lifetime
- 2004-02-26 AU AU2004216360A patent/AU2004216360B2/en not_active Ceased
- 2004-02-26 US US10/493,488 patent/US20060058336A1/en not_active Abandoned
- 2004-02-26 AT AT04714961T patent/ATE487492T1/de not_active IP Right Cessation
- 2004-02-26 JP JP2006502684A patent/JP2006519225A/ja active Pending
- 2004-02-26 EP EP04714961A patent/EP1603595B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO2004075916A1 (en) | 2004-09-10 |
EP1603595B1 (de) | 2010-11-10 |
AU2004216360A2 (en) | 2004-09-10 |
EP1603595A1 (de) | 2005-12-14 |
JP2006519225A (ja) | 2006-08-24 |
US20060058336A1 (en) | 2006-03-16 |
DE602004029993D1 (de) | 2010-12-23 |
CA2516618A1 (en) | 2004-09-10 |
AU2004216360B2 (en) | 2009-09-17 |
EP1603595A4 (de) | 2008-04-16 |
AU2004216360A1 (en) | 2004-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1106386T1 (el) | Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης | |
EA200700362A1 (ru) | Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью | |
DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
ATE413162T1 (de) | Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln | |
NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
BRPI0415858A (pt) | compostos de medicamentos terapêuticos modificados por tocoferol | |
EA200501702A1 (ru) | Устойчивая к манипуляциям дозировочная форма для трансдермального введения | |
CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
MY143795A (en) | Tetrahydropyridoindole derivatives | |
ATE550015T1 (de) | Verfahren und zusammensetzung zur behandlung von rhinitis | |
CY1113116T1 (el) | Υποκατεστημενες 4-αμινοκυκλοεξανολες | |
CY1109361T1 (el) | Υποκατεστημενες 4-αμινοκυκλοεξανολες | |
BR0314797A (pt) | Derivados da pirimidineamida e o uso dos mesmos | |
DE502004011851D1 (de) | Caspase 3, 8, 9 oder 10 Inhibitoren in Kombination mit MEK Inhibitoren zur Behandlung von Influenza | |
CY1107231T1 (el) | Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης | |
DE60326069D1 (de) | 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen | |
AR048672A1 (es) | Tabletas de desintegracion que comprenden licarbazepina | |
RS50148B (sr) | Upotreba docetaksela za lečenje hepatoćelijskog karcinoma | |
BRPI0518554A2 (pt) | uso de um inibidor de pde3 | |
ATE487492T1 (de) | Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit | |
ATE446763T1 (de) | Pharmazeutische formulierung zur behandlung von osteoarthritis mit clodronsäure und hyaluronsäure | |
ATE404192T1 (de) | Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration | |
AR040287A1 (es) | Plataforma para formulaciones transdermicas (pft) | |
ATE413171T1 (de) | Pharmazeutische zusammensetzungen mit ascorbinsäure zur behandlung von pilz- superinfektionen und pilz-rezidiven |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |